Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03213938
Other study ID # ZZ10-012
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 9, 2017
Est. completion date December 10, 2019

Study information

Verified date August 2022
Source Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) refers to the presence of bothersome pelvic pain symptoms without an identifiable cause. Common symptoms of CP/CPPS include discomfort in the perineum, suprapubic region, and lower urinary tract symptoms. It affects men of all ages without apparent racial predisposition, among which, 36-50 years old are the most commonly influenced. Yet, few effective therapies are available for treating CP/CPPS. Acupuncture may be an effective treatment option for CP/CPPS. However, effects of acupuncture on CP/CPPS remain uncertain because of the small sample sizes or other methodological limitations. The objective of this multi-centre, randomized, sham acupuncture-controlled trial is to assess the effectiveness of acupuncture for relieving symptoms of CP/CPPS. The results will provide a robust conclusion with a high level of evidence.


Recruitment information / eligibility

Status Completed
Enrollment 440
Est. completion date December 10, 2019
Est. primary completion date December 10, 2019
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - 1.History of pain perceived in the prostate region and absence of other lower urinary tract pathology for a minimum of three of the past 6 months. In addition, any associated lower urinary tract symptoms, sexual function, and psychological factors should be addressed. Physical examinations, urinary analyses, and urine cultures will be performed for all subjects; - 2. Age 18 to 50 years. - 3. NIH Chronic Prostatitis Symptom Index (NIH- CPSI) total score = 15. Exclusion Criteria: - 1. Prostate, bladder, or urethral cancer, seizure disorder in any medical history. - 2. Inflammatory bowel disease, active urethral stricture, neurologic disease or disorder affecting the bladder, liver disease, neurologic impairment or psychiatric disorder preventing understanding of consent and self-report scale. - 3. Urinary tract infection with a urine culture value of more than 100,000 CFU/mL, clinical evidence of urethritis, including urethral discharge or positive culture, diagnostic of sexually transmitted diseases (including gonorrhoea, chlamydia, mycoplasma or trichomonas, but not including HIV/AIDS), symptoms of acute or chronic epididymitis). - 4. Residual urine volume=100ML. - 5. Qmax=15ML/S. - 6. Prior 4 weeks used androgen hormone inhibitors (finasteride), alpha-blockers (terazosin HCI, doxazosin mesylate, tamsulosin hydrochloride), antibiotics (ciprofloxacin hydrochloride), or any other prostatitis-specific medication (including herb and Chinese medicine).

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Acupuncture
For acupuncture group, Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used. Bilateral SP6, BL33, BL23, and BL35, were selected as acupoints protocol. Acupuncture group consists of 20 sessions over an 8-week period after baseline, each for 30 minutes, and will be administered over 8 weeks (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks).
Sham acupuncture
For sham acupuncture group, Hwato brand disposable acupuncture needles (size 0.30 × 25mm) will be used to insert vertically about 2-3 mm without manipulation into non-acupoints bilateral sham SP6, sham BL33, sham BL23, and sham BL35, which were located at different physical locations than SP6, BL23, BL 33, and BL35. Sham acupuncture group consists of 20 sessions over an 8-week period after baseline, each for 30 minutes, and will be administered over 8 weeks (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks).

Locations

Country Name City State
China Guang'anmen Hospital, China Academy of Chinese Medical Science Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Country where clinical trial is conducted

China, 

References & Publications (2)

Qin Z, Liu Y, Zhou K, Wu J, Pang R, Li N, Xu C, Kwong JSW, Liu Z. Acupuncture for chronic prostatitis/chronic pelvic pain syndrome: study protocol for a randomized controlled trial. Trials. 2017 Dec 22;18(1):616. doi: 10.1186/s13063-017-2383-8. — View Citation

Sun Y, Liu Y, Liu B, Zhou K, Yue Z, Zhang W, Fu W, Yang J, Li N, He L, Zang Z, Su T, Fang J, Ding Y, Qin Z, Song H, Hu H, Zhao H, Mo Q, Zhou J, Wu J, Liu X, Wang W, Pang R, Chen H, Wang X, Liu Z. Efficacy of Acupuncture for Chronic Prostatitis/Chronic Pel — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Expectation Assessment Expectation assessment will be assessed at baseline, which includes 2 brief questions to investigate whether patients are confident that acupuncture treatment will help their CP/CPPS: "In general, is acupuncture effective for controlling the illness?", "Do you think acupuncture will helpful to improve your CP/CPPS symptoms?" For each question, participants could choose "Yes", "No" or "unclear" as the answer. baseline
Primary Proportion of Responders at the End of 8-week The responder is defined as who has a decline of 6 or more than 6-point from baseline measured by using the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI). week 8
Primary Proportion of Responders at the End of 32-week The responder is defined as who has a decline of 6 or more than 6-point from baseline measured by using the NIH-CPSI. week 32
Secondary Proportion of Responders at Other Time Points The responder is defined as who has a decline of 6 or more than 6-point from baseline measured by using the NIH-CPSI. weeks 1-7; week 20
Secondary the Change From Baseline in NIH-CPSI Total Score The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) is a universally accepted, reliable and valid instrument recommended for clinical evaluation and research of CP/CPPS by consensus guidelines. It measures the domains of pain (score range, 0-21), urinary function (0-10) and quality of life impact (0-12) in CP/CPPS, with a total score ranging from 0 to 43 and higher scores indicating worse conditions. weeks 1-8; week 20; week 32
Secondary the Change From Baseline in NIH-CPSI Subscales The NIH-CPSI is a universally accepted, reliable and valid instrument recommended for clinical evaluation and research of CP/CPPS by consensus guidelines. It measures the domains of pain, urinary function and quality of life impact in CP/CPPS. The score range of pain subscale is 0-21, with higher scores indicating worse conditions. The score range of urinary function subscale is 0-10, with higher scores indicating worse conditions. The score range of quality-of-life subscale is 0-12, with higher scores indicating worse quality of life. weeks 1-8; week 20; week 32
Secondary the Change From Baseline in the International Prostate Symptom Score (IPSS) IPSS is a valid, reliable and sensitive measure for patients with lower urinary tract symptoms; it is widely used in clinical practice and research to determine the severity of lower urinary tract symptoms, including incomplete bladder emptying, frequency of urination, intermittency, urgency, weak urine stream, straining and nocturia. Each of the questions is rated from 0 (not at all) to 5 (almost always). IPSS score ranges from 0 to 35, with higher score indicating more severe urinary symptoms. week 4; week 8; week 20; week 32
Secondary the Change From Baseline in the Hospital Anxiety and Depression Scale (HADS) HADS is made up of 7 items for the assessment of depression and anxiety; the completion of this scale usually requires 2-5 minutes. HADS score ranges from 0 to 42, with higher scores indicating greater anxiety and depression. week 8; week 20; week 32
Secondary the Change From Baseline in the International Index of Erectile Function 5 (IIEF-5) The IIEF-5 is a psychometrically valid and reliable instrument with high sensitivity and specificity for detecting treatment effects in patients with erection dysfunction of a broad spectrum of aetiology. Chinese version IIEF-5 score ranges from 0 to 25, with lower scores indicating greater severity of dysfunction and minimal clinical important difference over 5. week 8; week 20; week 32
Secondary the Change From Baseline in the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Questionnaire The EQ-5D-5L is a well-established and suitable for evaluation of quality of life in participants with CP/CPPS. EQ-5D-5L overall index ranges from -0.39 to 1.00, with higher overall index indicating better generic health-status. week 8; week 20; week 32
Secondary the Proportions of Participants in Each Response Category of the Global Response Assessment (GRA) GRA consists of 7 response categories: markedly worsened, moderately worsened, slightly worsened, no change, slightly improved, moderately improved, and markedly improved. week 4; week 8; week 20; week 32
Secondary the Change for Peak and Average Urinary Flow Rate From Baseline weeks 8 and 32
See also
  Status Clinical Trial Phase
Completed NCT04552431 - Chronic Prostatitis Collaborative Research Network Clinical Trial- Ciprofloxacin and Tamsulosin Phase 2
Not yet recruiting NCT05366517 - Repeating LiST for Refractory Non-bacterial Prostatitis/Pelvic Pain Syndrome N/A
Terminated NCT02385266 - Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain Phase 4
Completed NCT00672087 - Diagnostic Challenges in IC (and Male CPPS)
Recruiting NCT00775515 - Laparoscopic Prostatectomy for Chronic Prostatitis Phase 2
Completed NCT01676857 - Chemokine Mechanisms in Chronic Pelvic Pain
Recruiting NCT06299683 - Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment N/A
Completed NCT00826514 - An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis Phase 2
Completed NCT06064448 - Clinical Observation of Ningmitai Capsule in Treating Chronic Pelvic Pain Syndrome With Erectile Dysfunction Phase 4
Completed NCT04446598 - Management of Prostatodynia in Younger Patients With Non-ablative Erbium:YAG Intraurethral Laser N/A
Completed NCT00701311 - An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome Phase 2
Completed NCT04275297 - Optimizing Psychosocial Treatment of Interstitial Cystitis/Bladder Pain Syndrome N/A
Active, not recruiting NCT05075551 - Analyzing the Brain Alterations of Acupuncture on Patients With CP/CPPS Evaluated by fMRI N/A
Recruiting NCT06385977 - Risk Factors for Chronic Prostatitis Patients in Northwest China
Completed NCT06016595 - Chronic Prostatitis/Chronic Pelvic Pain Syndrome Patients
Active, not recruiting NCT01828996 - Shocking Therapy for Chronic Pelvic Pain Syndrome N/A
Recruiting NCT03629769 - Effects of Proxelan Somministration in Patients With Chronic Prostatitis Phase 3
Recruiting NCT06345014 - The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome Phase 4
Recruiting NCT06115083 - Effects of Pelvic Floor Training in Male Chronic Pelvic Pain, Correlation Between Subjective and Objective Outcomes N/A
Completed NCT03167216 - Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction Early Phase 1